Condition: Treatment-resistant Schizophrenia · Sponsor: Newron Pharmaceuticals SPA
This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in patients with documented treatment-resistant schizophrenia (TRS) who have prospectively demonstrated inadequate response to their current stable therapeutic dose of an antipsychotic(s). Approximately 400 patients will be randomized equally (1:1) to each of the two treatment groups in this study.
This description comes directly from the study's public registry record.
Newron Pharmaceuticals · +39 02 610 3461 · info@newron.com
Always discuss trial participation with your own doctor first.
| UCLA DGSOM, UCLA Health, UCLA Semel Institute | Los Angeles, California, United States | Suspended |
| University of Miami, Miller School of Medicine; Jackson Behavioral Health Hospital | Miami, Florida, United States | Suspended |
| Grady Behavioral Health Center, -Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine | Atlanta, Georgia, United States | Suspended |
| Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine | Baltimore, Maryland, United States | Suspended |
| Manhattan Psychiatric Center, The Nathan Kline Institute for Psychiatric Research | New York, New York, United States | Suspended |
| Help Hospital | Vijayawada, Andhra Pradesh, India | Not Yet Recruiting |
| Masina Hospital Trust | Mumbai, Maharashtra, India | Recruiting |
| Ahana Hospitals LLP | Madurai, Tamil Nadu, India | Recruiting |
| Udyan Health Care | Lucknow, Uttar Pradesh, India | Recruiting |
| Seth Sukhlal Karnani Memorial Hospital | Kolkata, West Bengal, India | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07184619